Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
about
Transmission of human hepatitis C virus from patients in secondary cells for long term cultureHepatitis C virus and vaccine developmentHepatitis C virus infection in san francisco’s HIV-infected urban poorCost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United StatesCost-effectiveness of Telaprevir combination therapy for chronic hepatitis CCandidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunitiesTaking account of future technology in cost effectiveness analysisEmerging PEGylated drugs.Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UKChronic liver disease mortality among male prison inmates in Texas, 1989-2003.HCV-related mortality among male prison inmates in Texas, 1994-2003.The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.Liver cancer mortality among male prison inmates in Texas, 1992-2003.Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India.Costs of treatment, follow-up, and complications of chronic hepatitis B and hepatitis C infections.Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.Economic burden of hepatitis C-associated diseases in the United States.Too much of a good thing? When to stop catch-up vaccinationNew combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0.Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studyCost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.The cost-effectiveness of screening for chronic hepatitis B infection in the United States.Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisCost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.Cost-effectiveness of screening for hepatitis C in Canada.Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China.The current economic burden of cirrhosis.Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccineManagement of chronic hepatitis C virus infection: a new era of disease control.Current status and future directions in the management of chronic hepatitis C.Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation.Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural EgyptEstimation of utilities for chronic hepatitis C from SF-36 scores.Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV.Cost-effectiveness and population outcomes of general population screening for hepatitis C.Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.
P2860
Q24800686-AA4F043B-E353-443F-A6DC-955B7F8BBB3CQ27001610-2C8EFD9C-6B4F-400F-9007-BDB1DB7F3797Q27473306-1EBA34A1-3056-47CB-B46E-AB0D85613B29Q28488762-9FF09469-B74C-40E5-9DEF-0A5C8D7E2D02Q28540562-68FDFCD1-1C8B-48DE-9D7C-15A484AFCFD2Q30226978-6C0340D5-D4FA-4578-9970-D99660878197Q30833185-A467A182-93C7-487B-9503-20F6BCAD6A1EQ33447691-D0C95CAF-11E4-422C-980A-B518DF590876Q33795154-800DAD5F-9A0D-48C4-8FD7-051981B969DDQ33799309-40EB3881-CE3B-47A2-8946-DBBACE7555FAQ33802968-A0D79E55-3323-46B9-AD98-6A71FBD3573BQ33834958-C26C9E3E-F812-4E2C-BBBF-404EF7151B6DQ33889865-B9D16BF2-9E24-4B1D-9C1F-E96E01482D35Q33969384-85208497-47D8-4C25-8153-4A7974051A2DQ33974105-7DC8AB84-F8E2-4438-AF79-28B44F855B87Q34098870-9E7DD846-DB53-40DD-AF74-C7C7134F05A6Q34253963-789BBEC4-07FB-484C-ACD7-0F1281B271BAQ34585496-8B00D7B1-D900-4A4A-8D3A-936CDAC6EE91Q34605687-2689091C-E32D-4B8A-91FA-8A727F3278D1Q34677310-CA5D1918-E7ED-4FD6-A0A0-F3762B1D3C26Q34690368-BBA2751B-E525-443F-8947-B0615B21906DQ34765761-28699D66-3FE2-4B8C-8EF7-C67F425A2C59Q34990604-D118A9A6-F203-47F6-8C4F-F707A4195DFDQ35037688-7081A910-4FFD-4ECF-9B06-48EAB729B315Q35058571-D32C664A-FDB0-4BF0-AB29-02495BADE498Q35088460-0ECB0C31-2EB2-42E1-90EF-411878AF9594Q35597434-832A0818-98F1-4A1E-9D19-19672B8D4646Q35632910-D13042DC-8116-4961-8574-74B0B195BF8AQ35691411-B21024AD-B731-4BAE-A2E3-2E7071F2D7CCQ35736293-11C82266-B044-4E1E-9D75-855E695D8791Q35771272-2DE5C4A0-035E-42C8-9842-B43BE6A25756Q35823410-D13ECCDB-2834-49A2-A093-CEE6D62EC844Q35887719-FADF5E5D-48E1-4846-A152-53AC6B8340A9Q35903650-8496F8A7-DA05-434B-A9EB-ACA7D60FDC4CQ36020207-39FD00EA-B85D-45F9-919D-7C4642A41C7EQ36060018-E634B047-A948-449E-BC84-55CA63DB8AD4Q36083457-B71B0AEF-7C86-4348-BCE6-61060BF9938EQ36115516-2ED1912D-BE4E-4573-88FE-A7D0524D361BQ36179730-60196C0B-1B73-4A41-89A1-D7D3A7B17D21Q36272393-99511F8F-DBF5-4347-8B19-0A557A749FAF
P2860
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Cost-effectiveness of treatmen ...... n evolving patient population.
@en
Cost-effectiveness of treatmen ...... n evolving patient population.
@nl
type
label
Cost-effectiveness of treatmen ...... n evolving patient population.
@en
Cost-effectiveness of treatmen ...... n evolving patient population.
@nl
prefLabel
Cost-effectiveness of treatmen ...... n evolving patient population.
@en
Cost-effectiveness of treatmen ...... n evolving patient population.
@nl
P50
P356
P1476
Cost-effectiveness of treatmen ...... n evolving patient population.
@en
P2093
Joshua A Salomon
P304
P356
10.1001/JAMA.290.2.228
P407
P577
2003-07-01T00:00:00Z